Protara Therapeutics Inc. has announced the initiation of patient dosing in the Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous (IV) Choline Chloride in patients receiving long-term parenteral support. The investigational therapy, previously granted Fast Track designation by the U.S. Food and Drug Administration, is being studied as a potential treatment for choline deficiency in patients unable to receive adequate nutrition through oral or enteral means. The THRIVE-3 trial is designed to assess the efficacy and safety of low and high dose IV Choline Chloride, with a primary endpoint of change in plasma choline concentration from baseline compared to placebo. An interim analysis from the trial is expected in the second half of 2026. Results from the study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protara Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621262) on January 07, 2026, and is solely responsible for the information contained therein.